TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15179638

Group type: EXPERIMENTAL
Intervention: Water-based exercise program (chest-deep water, 1 hour, 3 times a week for 8 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Water-based exercise program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Upper-extremity function program (control group, arm and hand exercises while sitting)
Number of subjects: 12
Study: 11473071

Group type: EXPERIMENTAL
Intervention: Quality improvement program (clinical practice guidelines, postgraduate education, audit and feedback, templates to register diabetes care, recall system)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Reference group (no specific intervention mentioned)
Number of subjects: 389
Study: 9749737

Group type: EXPERIMENTAL
Intervention: Word 'long'
Number of subjects: 6

Group type: COMPARATOR
Intervention: Word 'short'
Number of subjects: 6
Study: 7831635

Group type: EXPERIMENTAL
Intervention: Baker Norton metered dose inhaler with Volumatic
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ventolin metered dose inhaler with Volumatic
Number of subjects: 11
Study: 3229560

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 99

Group type: COMPARATOR
Intervention: Psychological placebo
Number of subjects: 99

Group type: COMPARATOR
Intervention: Own best efforts
Number of subjects: 99
Study: 29852092

Group type: EXPERIMENTAL
Intervention: RT5 (5 times weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RT3 (3 times weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RT2 (2 times weekly)
Number of subjects: 20
Study: 26349445

Group type: EXPERIMENTAL
Intervention: Online video cyberbullying prevention program
Number of subjects: 167

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 167
Study: 25274918

Group type: EXPERIMENTAL
Intervention: Standardised forced leg extension assessment pre-operatively and at 6 and 26 weeks post-operatively
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group of patients who underwent primary TKR
Number of subjects: 25
Study: 21381807

Group type: EXPERIMENTAL
Intervention: Smoking (cigarette)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No smoking (control)
Number of subjects: 132
Study: 20137762

Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg everolimus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of sotrastaurin and everolimus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin with 2 mg everolimus
Number of subjects: 18
Study: 17667565

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-free anesthesia (80% oxygen, 20% nitrogen)
Number of subjects: 2050

Group type: COMPARATOR
Intervention: Nitrous oxide-based anesthesia (70% N2O, 30% oxygen)
Number of subjects: 2050
Study: 16146460

Group type: EXPERIMENTAL
Intervention: Post-operative autotransfusion of mediastinal shed blood
Number of subjects: 50

Group type: COMPARATOR
Intervention: No autotransfusion
Number of subjects: 50
Study: 11875167

Group type: EXPERIMENTAL
Intervention: Modified-release methylphenidate (MPH MR)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 7589640

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d orally for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy with E2 patches and medroxyprogesterone acetate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2384192

Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test (OGTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ensure-Plus challenge test (EPCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical tests including hemoglobin, glycosylated hemoglobin, plasma cholesterol, triglycerides, and lipoproteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine collections for C-peptide and creatinine
Number of subjects: 0
Study: 90965

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol daily from admission
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31760780

Group type: EXPERIMENTAL
Intervention: 6 h time in bed (TIB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 8 h time in bed (TIB)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Delayed bedtime by 2 hours nightly
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Monitoring changes in daily affect
Number of subjects: 58
Study: 31884935

Group type: EXPERIMENTAL
Intervention: Fast Dissolving Tablets (FDT) of Febuxostat
Number of subjects: 0
Study: 30824248

Group type: EXPERIMENTAL
Intervention: d-cycloserine
Number of subjects: 91

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study: 28219612

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FiO2 at 1.0)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Normoxia (FiO2 target 88-95%)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3.0%)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Isotonic saline (0.9%)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 442

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 442
Study: 27601592

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide-based chemotherapy
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Non-luminal A subtypes
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control (no systematic treatment)
Number of subjects: 709
Study: 24020831

Group type: EXPERIMENTAL
Intervention: Physical HRQoL
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Mental HRQoL
Number of subjects: 430
Study: 21378175

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) based on 34 type 2 diabetes-associated loci
Number of subjects: 2843

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 2843
Study: 19567380

Group type: EXPERIMENTAL
Intervention: Protect group (Medtronic Insync III Protect device)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (other Medtronic CRT-D devices)
Number of subjects: 324
Study: 17337369

Group type: EXPERIMENTAL
Intervention: Preemptive local infiltration (PLA) with 20 mL of 0.2% ropivacaine diluted with 80 mL of 0.9% saline (total volume 100 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative wound infiltration (POW) of 20 mL of 0.2% ropivacaine (40 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preemptive local infiltration (PLA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative wound infiltration (POW)
Number of subjects: 30
Study: 15529256

Group type: EXPERIMENTAL
Intervention: Parenteral influenza vaccination
Number of subjects: 0
Study: 11297828

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg (iv) morphine
Number of subjects: 84
Study: 10027666

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for two weeks
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg q.i.d. for two weeks
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Patients with oesophagitis
Number of subjects: 427
Study: 8085732

Group type: EXPERIMENTAL
Intervention: Oral antimicrobials
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Topical antipseudomonal agents
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 246
Study: 2666565

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 61340

Group type: EXPERIMENTAL
Intervention: Intravenous oxprenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control studies (no drug)
Number of subjects: 5
Study: 31627041

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 103
Study: 28975600

Group type: EXPERIMENTAL
Intervention: VR group (4-min video of Pororo visiting the operating theatre)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (conventional information regarding anaesthesia and surgery)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 26355616

Group type: EXPERIMENTAL
Intervention: CO2 facial treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Microdermabrasion
Number of subjects: 12
Study: 23271211

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 786

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Comparison of embryo transfer cycles
Number of subjects: 786
Study: 20598758

Group type: EXPERIMENTAL
Intervention: Adapted leisure education program
Number of subjects: 49
Study: 19584328

Group type: EXPERIMENTAL
Intervention: African American patients with early-stage premenopausal breast cancer
Number of subjects: 19457

Group type: EXPERIMENTAL
Intervention: African American patients with early-stage postmenopausal breast cancer
Number of subjects: 19457

Group type: EXPERIMENTAL
Intervention: African American patients with advanced-stage ovarian cancer
Number of subjects: 19457

Group type: EXPERIMENTAL
Intervention: African American patients with advanced-stage prostate cancer
Number of subjects: 19457

Group type: COMPARATOR
Intervention: All other patients (non-African American)
Number of subjects: 19457
Study: 17058830

Group type: EXPERIMENTAL
Intervention: Sodium ferulate (SF) 300 mg/d intravenously for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment including dietary therapy and hypodermic injection of insulin
Number of subjects: 80
Study: 14762655

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 12 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11519354

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide cream (generic drug)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream (brand name)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle control (no active treatment)
Number of subjects: 20
Study: 9216708

Group type: EXPERIMENTAL
Intervention: 5'DFUR + OK-432
Number of subjects: 50

Group type: COMPARATOR
Intervention: OK-432
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 50
Study: 7853678

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) administered at a dose of 60-90 mg/kg divided into 3 dosages via 30-minute intravenous drip infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at a dose of 20 mg/kg via 30-minute intravenous drip infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at a dose of 10 mg/kg via 30-minute intravenous drip infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at doses of 20 and 10 mg/kg via 30-minute intravenous infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) administered to patients with various infections
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP)
Number of subjects: 17
Study: 3376911

Group type: EXPERIMENTAL
Intervention: High Mono diet (high in monounsaturates, low in cholesterol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low Fat diet (low in fat, high in carbohydrates, low in cholesterol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High Sat + Chol diet (high in saturated fatty acids and very high in cholesterol)
Number of subjects: 10
Study: 31192831

Group type: EXPERIMENTAL
Intervention: Yoga breathing (pranayama)
Number of subjects: 0
Study: 29151700

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: LAM+ADV
Number of subjects: 46
Study: 25784709

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 30
Study: 24649780

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO4) 50 mg kg(‐1) in 10 mL within 10 min, followed by an infusion of MgSO4 10 mg kg(‐1) hr(‐1) IV in 4mL for 12 hrs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (NS) in same volume and rate for 12 hrs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 60
Study: 22016437

Group type: EXPERIMENTAL
Intervention: Structured risk assessment scales on experimental wards
Number of subjects: 597

Group type: COMPARATOR
Intervention: Clinical judgement on control wards
Number of subjects: 597
Study: 18430311

Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 16436687

Group type: EXPERIMENTAL
Intervention: Olfactory identification and recognition tasks in patients with MHE
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation between olfactory tests and PSE-syndrome test score
Number of subjects: 12
Study: 14701947

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily) and metronidazole (200 mg thrice daily for 7 days (Group 3)
Number of subjects: 165
Study: 11124072

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case-control and cohort studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine indices of benefit and harm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional statistical methods
Number of subjects: 0
Study: 9070501

Group type: EXPERIMENTAL
Intervention: 25 mg dolasetron mesylate
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron mesylate
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 100 mg dolasetron mesylate
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron mesylate
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control (no dolasetron)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: All doses of dolasetron
Number of subjects: 319
Study: 8348504

Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin (50 mg per instillation)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) (150 mg per instillation)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (resection only)
Number of subjects: 161
Study: 2948430

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.02 mL/kg of a 0.5% solution)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (2 mL of a 0.025% solution)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salbutamol plus ipratropium combination
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Half-dose or full-dose combinations of salbutamol and ipratropium
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 48
Study: 30025399

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 150
Study: 25914397

Group type: EXPERIMENTAL
Intervention: Single stent
Number of subjects: 577

Group type: COMPARATOR
Intervention: Double stent
Number of subjects: 577

Group type: COMPARATOR
Intervention: Bail-out double stenting
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Overall treatment with zotarolimus-eluting stents
Number of subjects: 577
Study: 25917626

Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (6 weekly doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (8 weekly doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (eight doses, two clustered increasing doses over 3 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study: 22642712

Group type: EXPERIMENTAL
Intervention: Stage theories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Order threats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage theory on Alzheimer's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threat on theory preference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed order of stages
Number of subjects: 0
Study: 20975274

Group type: EXPERIMENTAL
Intervention: Topiramate at a mean dose of 200 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Naltrexone at a mean dose of 50 mg/day
Number of subjects: 182
Study: 19055986

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) in ARTS-II trial
Number of subjects: 607
Study: 17003665

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12710563

Group type: EXPERIMENTAL
Intervention: Questionnaire exploring issues of information, informed consent, bio‐material, confidentiality and autonomy, and of prevention/intervention
Number of subjects: 17055
Study: 10764850

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Presenting visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Best visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Best visual acuity 0.5 or worse in both eyes
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Refractive error as a cause of reduced uncorrected vision
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Amblyopia as a cause of reduced uncorrected vision
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Other causes of reduced uncorrected vision
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Unexplained causes of reduced uncorrected vision
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Myopia (‐0.5 diopter or less) or hyperopia (2 diopters or greater)
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Hyperopia risk
Number of subjects: 5067

Group type: EXPERIMENTAL
Intervention: Myopia risk
Number of subjects: 5067
Study: 8610733

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 35
Study: 1414298

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium sucrose sulphate solution
Number of subjects: 0
Study: 6379293

Group type: EXPERIMENTAL
Intervention: Patients with multiple trauma
Number of subjects: 26

Group type: COMPARATOR
Intervention: Controls (normals)
Number of subjects: 26
Study: 31499238

Group type: EXPERIMENTAL
Intervention: Hand gel sanitizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30423587

Group type: EXPERIMENTAL
Intervention: Baclofen (BA group, n=112)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTI group, n=112)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo (physical therapies alone, n=112)
Number of subjects: 336
Study: 26420517

Group type: EXPERIMENTAL
Intervention: Placebo pill with sedative information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sham magnetic field
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 24768204

Group type: EXPERIMENTAL
Intervention: Interactive discussion group (5-hour group discussion about suicide risk assessment skills)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (2-hour baseline suicide gatekeeper lecture)
Number of subjects: 111
Study: 21987409

Group type: EXPERIMENTAL
Intervention: TachoSil (collagen patch coated with human coagulation factors)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard technique only
Number of subjects: 58
Study: 20163243

Group type: EXPERIMENTAL
Intervention: rhBMP‐2
Number of subjects: 16

Group type: COMPARATOR
Intervention: iliac crest bone graft
Number of subjects: 16
Study: 18025885

Group type: EXPERIMENTAL
Intervention: ART initiation in patients with pre-ART CD4 cell count < 200 cells/mul
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: ART initiation in patients with pre-ART CD4 cell count 200-350 cells/mul
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: ART initiation in patients with pre-ART CD4 cell count > 350 cells/mul
Number of subjects: 792
Study: 16054395

Group type: EXPERIMENTAL
Intervention: Maximal isometric contractions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maximal firing rates in the TA muscle
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Decrease in motor unit firing rate with fatigue
Number of subjects: 19
Study: 12124856

Group type: EXPERIMENTAL
Intervention: Low-dose extract of Tripterygium wilfordii Hook F (180 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-dose extract of Tripterygium wilfordii Hook F (360 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Open-label extension (Low-dose)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Open-label extension (High-dose)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Open-label extension (Placebo)
Number of subjects: 35
Study: 10466239

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy with conventional regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0
Study: 7573018

Group type: COMPARATOR
Intervention: Traditional Dialysate (TD; ionized calcium concentration 1.75 mmol/L)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low Calcium Dialysate (LCD; ionized calcium concentration 1.25 mmol/L)
Number of subjects: 86
Study: 1979010

Group type: COMPARATOR
Intervention: Droperidol-fentanyl anaesthesia (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Droperidol-fentanyl anaesthesia modified by addition of 0.5% isoflurane (isoflurane group)
Number of subjects: 20